Iovance Biotherapeutics Inc
IOVA1.750USD
-1.420-44.79%
Close 05/09, 16:00（ET）Quotes delayed by 15 min
534.19MMarket Cap
LossP/E TTM
More Details of Iovance Biotherapeutics Inc Company
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Company Info
Company codeIOVA
Company nameIovance Biotherapeutics Inc
IPO dateJun 20, 2008
Founded at2017
CEODr. Frederick G. Vogt, J.D., Ph.D.
Number of employees838
Security typeOrdinary Share
Fiscal year-endJun 20
Address825 Industrial Road
CitySAN CARLOS
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94070
Phone16502607120
Websitehttps://www.iovance.com/
Company codeIOVA
IPO dateJun 20, 2008
Founded at2017
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
349.65K
+3.55%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
87.58K
+1.61%
Mr. Jean-Marc Bellemin
Mr. Jean-Marc Bellemin
Chief Financial Officer
Chief Financial Officer
56.20K
-8.97%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
349.65K
+3.55%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
87.58K
+1.61%
Mr. Jean-Marc Bellemin
Mr. Jean-Marc Bellemin
Chief Financial Officer
Chief Financial Officer
56.20K
-8.97%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sun, May 4
Update time: Sun, May 4
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.23%
MHR Fund Management LLC
7.31%
Perceptive Advisors LLC
6.62%
BlackRock Institutional Trust Company, N.A.
6.15%
Other
63.28%
Shareholder Statistics
Shareholder
Proportion
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.23%
MHR Fund Management LLC
7.31%
Perceptive Advisors LLC
6.62%
BlackRock Institutional Trust Company, N.A.
6.15%
Other
63.28%
Type
Shareholder
Proportion
Investment Advisor
24.77%
Investment Advisor/Hedge Fund
21.77%
Private Equity
13.95%
Hedge Fund
8.74%
Venture Capital
8.50%
Research Firm
3.25%
Bank and Trust
0.70%
Pension Fund
0.54%
Individual Investor
0.31%
Other
17.47%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
658
278.41M
85.05%
-24.34M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
2023Q1
607
232.93M
108.05%
+12.27M
2022Q4
639
197.16M
124.92%
+7.22M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Quogue Capital L.L.C.
28.07M
8.56%
+5.00M
+21.68%
Feb 20, 2024
The Vanguard Group, Inc.
27.48M
8.38%
+210.50K
+0.77%
Dec 31, 2024
MHR Fund Management LLC
24.42M
7.45%
+420.00K
+1.75%
Dec 31, 2024
Perceptive Advisors LLC
22.11M
6.74%
-4.51M
-16.93%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
20.17M
6.15%
+1.46M
+7.80%
Dec 31, 2024
State Street Global Advisors (US)
12.25M
3.74%
-952.70K
-7.22%
Dec 31, 2024
Hood River Capital Management LLC
8.99M
2.74%
+846.94K
+10.40%
Dec 31, 2024
Soleus Capital Management, L.P.
6.56M
2%
-1.97M
-23.08%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.87M
1.79%
+222.43K
+3.94%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
5.83M
1.78%
-26.82K
-0.46%
Dec 31, 2024
View more
Related ETFs
Update time: Tue, May 6
Update time: Tue, May 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
1.21%
WisdomTree BioRevolution Fund
0.76%
Virtus LifeSci Biotech Products ETF
0.69%
Range Cancer Immunotherapy ETF
0.6%
SPDR S&P Biotech ETF
0.29%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco Nasdaq Biotechnology ETF
0.11%
iShares Biotechnology ETF
0.08%
Strive Small-Cap ETF
0.06%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion1.21%
WisdomTree BioRevolution Fund
Proportion0.76%
Virtus LifeSci Biotech Products ETF
Proportion0.69%
Range Cancer Immunotherapy ETF
Proportion0.6%
SPDR S&P Biotech ETF
Proportion0.29%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.18%
ProShares Ultra Nasdaq Biotechnology
Proportion0.11%
Invesco Nasdaq Biotechnology ETF
Proportion0.11%
iShares Biotechnology ETF
Proportion0.08%
Strive Small-Cap ETF
Proportion0.06%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data